Merck (MRK) Tops Q2 EPS by 5c; Narrows and Raise FY15 EPS Outlook
Get Alerts MRK Hot Sheet
EPS Growth %: +47.9%
Financial Fact:
Research and development: 5.14B
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Merck (NYSE: MRK) reported Q2 EPS of $0.86, $0.05 better than the analyst estimate of $0.81. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.8 billion.
Merck sees FY2015 EPS of $3.45-$3.55, versus the consensus of $3.45.
“We’re investing resources to grow our strongest brands and to support the most promising assets in our pipeline, while at the same time lowering our cost base and delivering operating leverage.”
“We’ve made significant progress this quarter in two of our most important assets, the KEYTRUDA and hepatitis C programs, and will be fully prepared to take advantage of these potentially breakthrough opportunities.”
“We’re witnessing the introduction of breakthrough therapies for some of the most difficult-to-treat diseases. Merck’s late-stage pipeline and ongoing launches reflect scientific and therapeutic progress with the potential to provide significant value to patients and society.”
For earnings history and earnings-related data on Merck (MRK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Macatawa Bank (MCBC) Misses Q1 EPS by 1c
- Merck (MRK) hikes outlook for 2024 as Q1 print beats analyst estimates
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!